Movement Disorders

Here's what is coming soon to NeurologyLive.

We kindly ask you to share 5 minutes of your time with us in order to help us better understand how you use social media and how we can better serve you across different platforms.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 25, 2021.

Calli L. Cook, NP, DNP, nurse practitioner, Woodruff School of Nursing, Emory University, detailed her vision for creating change within the neurology field by incorporating advanced practice clinicians.

Aristide Merola, MD, PhD, leads a discussion about the burden and impairment on the quality of life for patients with advanced Parkinson disease.

Experts in the field of Parkinson disease kick off a discussion about recognizing and managing the disease by defining advanced Parkinson disease.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 18, 2021.

The nurse practitioner at the Woodruff School of Nursing at Emory University detailed why a cultural shift is needed to incorporate APCs into the neurology space and thus improve multidisciplinary care.

Bayer provided an update on their phase 1 and 1b studies of dopaminergic neurons and GDNF gene therapy, respectively, for the treatment of PD.

Despite a few surprising program failures early this year, there is plenty of potential worth holding on to in the Huntington disease pipeline.

Here's what is coming soon to NeurologyLive.

When paired with the Percept PC device, SenSight expands on BrainSense technology, enabling clinicians to capture and record enhanced, directional local field potential information from the implanted lead.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 11, 2021.

For patients treated with pimavanserin in investigational doses of 8.5 mg or 17 mg in the previous studies, further improvement was observed during the open-label extension with 34-mg pimavanserin.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 4, 2021.

Serum tumor necrosis factor and glutathione levels decreased, and brain-derived neurotrophic factor levels increased significantly after treatment with electroCore’s gammaCore nVNS device.

Despite identifying a role of air pollutants in PD, no evidence for the association between the risk of PD and exposure to particulate matters, ozone, sulfur dioxide, or carbon monoxide were observed.

The assistant professor of neurology at the Keck School of Medicine at University of Southern California discussed the importance of having additional agents to treat Parkinson disease.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending May 29, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 28, 2021.

Alterations in MDS-UPDRS part III scores were associated with increased expression of Treg phenotypes and immunosuppressive function, suggesting a potential role of Treg function in diminution of disease progression.

With successful completion of the phase 2a study, Annovis plans on evaluating ANVS401 in late-stage studies starting in late 2021.

An upcoming phase 2 trial will assess ketamine in up to 36 patients, using change in the Unified Dyskinesia Rating Scale as the primary end point of the study.

Here's what is coming soon to NeurologyLive.

The findings suggest that patients with dementia should be prioritized for stringent preventive measures, greater surveillance, and early intervention in COVID-19.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 21, 2021.

A budget impact analysis suggested that Cala Health’s Cala Trio device can serve as a cost-saving treatment option for patients with ET.